Zai Lab (ZLAB) Stock Forecast, Price Target & Predictions
ZLAB Stock Forecast
Zai Lab stock forecast is as follows: an average price target of $75.50 (represents a 144.42% upside from ZLAB’s last price of $30.89) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
ZLAB Price Target
ZLAB Analyst Ratings
Zai Lab Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Sep 27, 2024 | Jack Lin | Morgan Stanley | $50.00 | $23.63 | 111.60% | 61.86% |
Apr 21, 2022 | - | Leerink Partners | $101.00 | $42.88 | 135.54% | 226.97% |
Zai Lab Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 1 | 1 |
Avg Price Target | - | $50.00 | $50.00 |
Last Closing Price | $30.89 | $30.89 | $30.89 |
Upside/Downside | -100.00% | 61.86% | 61.86% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 27, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
Apr 09, 2024 | Bank of America Securities | Buy | Buy | Hold |
Oct 26, 2023 | Goldman Sachs | Buy | Buy | Hold |
Zai Lab Financial Forecast
Zai Lab Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | $69.23M | $68.86M | $62.80M | $62.60M | $57.54M | $48.18M | $46.72M | $44.17M | $43.10M | $36.94M | $20.10M | $15.09M | $14.65M | $10.99M | $8.22M | $4.65M |
Avg Forecast | $137.50M | $130.30M | $123.00M | $117.30M | $107.20M | $102.24M | $93.16M | $75.24M | $72.14M | $66.41M | $70.48M | $65.12M | $62.79M | $53.75M | $47.13M | $44.58M | $47.89M | $43.77M | $27.41M | $17.66M | $25.45M | $15.83M | $-1.64M | $36.00K | $10.00M |
High Forecast | $137.50M | $130.30M | $123.00M | $117.30M | $107.20M | $106.68M | $93.16M | $75.24M | $76.07M | $69.27M | $70.48M | $65.12M | $62.79M | $53.75M | $47.13M | $44.58M | $47.89M | $43.77M | $27.41M | $17.66M | $25.45M | $15.83M | $-1.64M | $36.00K | $10.00M |
Low Forecast | $137.50M | $130.30M | $123.00M | $117.30M | $107.20M | $99.52M | $93.16M | $75.24M | $67.70M | $63.55M | $70.48M | $65.12M | $62.79M | $53.75M | $47.13M | $44.58M | $47.89M | $43.77M | $27.41M | $17.66M | $25.45M | $15.83M | $-1.64M | $36.00K | $10.00M |
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 |
Surprise % | - | - | - | - | - | - | - | - | - | 1.04% | 0.98% | 0.96% | 1.00% | 1.07% | 1.02% | 1.05% | 0.92% | 0.98% | 1.35% | 1.14% | 0.59% | 0.93% | -6.71% | 228.28% | 0.46% |
Zai Lab EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 |
EBITDA | - | - | - | - | - | - | - | - | - | $-83.57M | $-89.50M | $-78.43M | $-136.00M | $-126.36M | $-96.86M | $-77.75M | $-209.95M | $-94.78M | $-161.80M | $-231.46M | $-75.14M | $-62.55M | $-79.54M | $-46.86M | $-45.14M |
Avg Forecast | $-137.50M | $-130.30M | $-123.00M | $-117.30M | $-107.20M | $-102.24M | $-93.16M | $-75.24M | $-72.14M | $-66.41M | $-70.48M | $-65.12M | $-16.95M | $-53.75M | $-47.13M | $-44.58M | $-47.89M | $-43.77M | $-27.41M | $-178.77M | $-25.45M | $-15.83M | $1.64M | $-36.00K | $-18.13M |
High Forecast | $-137.50M | $-130.30M | $-123.00M | $-117.30M | $-107.20M | $-99.52M | $-93.16M | $-75.24M | $-67.70M | $-63.55M | $-70.48M | $-65.12M | $-13.56M | $-53.75M | $-47.13M | $-44.58M | $-47.89M | $-43.77M | $-27.41M | $-143.01M | $-25.45M | $-15.83M | $1.64M | $-36.00K | $-14.50M |
Low Forecast | $-137.50M | $-130.30M | $-123.00M | $-117.30M | $-107.20M | $-106.68M | $-93.16M | $-75.24M | $-76.07M | $-69.27M | $-70.48M | $-65.12M | $-20.34M | $-53.75M | $-47.13M | $-44.58M | $-47.89M | $-43.77M | $-27.41M | $-214.52M | $-25.45M | $-15.83M | $1.64M | $-36.00K | $-21.75M |
Surprise % | - | - | - | - | - | - | - | - | - | 1.26% | 1.27% | 1.20% | 8.02% | 2.35% | 2.06% | 1.74% | 4.38% | 2.17% | 5.90% | 1.29% | 2.95% | 3.95% | -48.56% | 1301.64% | 2.49% |
Zai Lab Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 |
Net Income | - | - | - | - | - | - | - | - | - | $-69.15M | $-120.89M | $-28.77M | $-26.25M | $-158.96M | $-136.07M | $-84.80M | $-203.94M | $-109.28M | $-155.67M | $-238.92M | $-57.39M | $-50.96M | $-77.02M | $-49.52M | $-40.56M |
Avg Forecast | $-27.33M | $-50.26M | $-54.16M | $-56.60M | $-79.36M | $-76.40M | $-69.13M | $-90.26M | $-83.52M | $-101.90M | $-77.14M | $-92.53M | $-17.43M | $-121.87M | $-104.98M | $-122.99M | $-130.17M | $-114.98M | $-103.61M | $-179.89M | $-165.42M | $-165.42M | $-58.10M | $-61.42M | $-18.65M |
High Forecast | $-27.33M | $-50.26M | $-54.16M | $-56.60M | $-79.36M | $-69.27M | $-69.13M | $-90.26M | $-74.88M | $-101.90M | $-77.14M | $-92.53M | $-13.95M | $-121.87M | $-104.98M | $-122.99M | $-130.17M | $-114.98M | $-103.61M | $-143.91M | $-165.42M | $-165.42M | $-58.10M | $-61.42M | $-14.92M |
Low Forecast | $-27.33M | $-50.26M | $-54.16M | $-56.60M | $-79.36M | $-85.57M | $-69.13M | $-90.26M | $-93.12M | $-101.90M | $-77.14M | $-92.53M | $-20.92M | $-121.87M | $-104.98M | $-122.99M | $-130.17M | $-114.98M | $-103.61M | $-215.86M | $-165.42M | $-165.42M | $-58.10M | $-61.42M | $-22.37M |
Surprise % | - | - | - | - | - | - | - | - | - | 0.68% | 1.57% | 0.31% | 1.51% | 1.30% | 1.30% | 0.69% | 1.57% | 0.95% | 1.50% | 1.33% | 0.35% | 0.31% | 1.33% | 0.81% | 2.18% |
Zai Lab SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 |
SG&A | - | - | - | - | - | - | - | - | - | $68.55M | $67.92M | $62.51M | $72.02M | $66.56M | $63.40M | $56.99M | $69.58M | $59.00M | $54.41M | $35.84M | $40.97M | $27.87M | $23.76M | $18.71M | $23.02M |
Avg Forecast | $315.08M | $298.58M | $281.85M | $268.79M | $245.65M | $234.28M | $213.48M | $8.42M | $165.31M | $152.17M | $161.50M | $9.00M | $8.65M | $123.16M | $107.98M | $9.63M | $109.75M | $100.31M | $62.80M | $40.46M | $58.32M | $36.28M | $-3.75M | $82.49K | $9.25M |
High Forecast | $315.08M | $298.58M | $281.85M | $268.79M | $245.65M | $244.45M | $213.48M | $10.10M | $174.32M | $158.73M | $161.50M | $10.80M | $10.37M | $123.16M | $107.98M | $11.55M | $109.75M | $100.31M | $62.80M | $40.46M | $58.32M | $36.28M | $-3.75M | $82.49K | $11.10M |
Low Forecast | $315.08M | $298.58M | $281.85M | $268.79M | $245.65M | $228.05M | $213.48M | $6.73M | $155.14M | $145.62M | $161.50M | $7.20M | $6.92M | $123.16M | $107.98M | $7.70M | $109.75M | $100.31M | $62.80M | $40.46M | $58.32M | $36.28M | $-3.75M | $82.49K | $7.40M |
Surprise % | - | - | - | - | - | - | - | - | - | 0.45% | 0.42% | 6.95% | 8.33% | 0.54% | 0.59% | 5.92% | 0.63% | 0.59% | 0.87% | 0.89% | 0.70% | 0.77% | -6.33% | 226.86% | 2.49% |
Zai Lab EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 |
EPS | - | - | - | - | - | - | - | - | - | $-0.71 | $-0.00 | $-0.30 | $-0.27 | $-1.66 | $-1.42 | $-0.89 | $-2.15 | $-1.15 | $-1.67 | $-2.70 | $-0.65 | $-0.68 | $-1.03 | $-0.68 | $-0.56 |
Avg Forecast | $-0.28 | $-0.52 | $-0.56 | $-0.58 | $-0.81 | $-0.78 | $-0.71 | $-0.92 | $-0.86 | $-1.04 | $-0.79 | $-0.95 | $-1.11 | $-1.25 | $-1.08 | $-1.26 | $-1.33 | $-1.18 | $-1.06 | $-1.58 | $-1.70 | $-1.70 | $-0.60 | $-0.63 | $-0.94 |
High Forecast | $-0.28 | $-0.52 | $-0.56 | $-0.58 | $-0.81 | $-0.71 | $-0.71 | $-0.92 | $-0.77 | $-1.04 | $-0.79 | $-0.95 | $-1.11 | $-1.25 | $-1.08 | $-1.26 | $-1.33 | $-1.18 | $-1.06 | $-1.58 | $-1.70 | $-1.70 | $-0.60 | $-0.63 | $-0.94 |
Low Forecast | $-0.28 | $-0.52 | $-0.56 | $-0.58 | $-0.81 | $-0.88 | $-0.71 | $-0.92 | $-0.95 | $-1.04 | $-0.79 | $-0.95 | $-1.11 | $-1.25 | $-1.08 | $-1.26 | $-1.33 | $-1.18 | $-1.06 | $-1.58 | $-1.70 | $-1.70 | $-0.60 | $-0.63 | $-0.94 |
Surprise % | - | - | - | - | - | - | - | - | - | 0.68% | 0.00% | 0.32% | 0.24% | 1.33% | 1.32% | 0.71% | 1.61% | 0.98% | 1.57% | 1.71% | 0.38% | 0.40% | 1.73% | 1.08% | 0.60% |
Zai Lab Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
APLS | Apellis Pharmaceuticals | $28.56 | $76.13 | 166.56% | Buy |
ZLAB | Zai Lab | $30.89 | $75.50 | 144.42% | Buy |
ERAS | Erasca | $2.87 | $7.00 | 143.90% | Buy |
CCCC | C4 Therapeutics | $6.45 | $13.50 | 109.30% | Buy |
CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
LEGN | Legend Biotech | $43.61 | $82.62 | 89.45% | Buy |
ASND | Ascendis Pharma | $125.77 | $190.21 | 51.24% | Buy |
AKRO | Akero Therapeutics | $32.05 | $46.00 | 43.53% | Buy |
ROIV | Roivant Sciences | $11.53 | $16.21 | 40.59% | Buy |
BPMC | Blueprint Medicines | $91.88 | $109.71 | 19.41% | Buy |
PTCT | PTC Therapeutics | $40.39 | $46.50 | 15.13% | Hold |
KRYS | Krystal Biotech | $170.85 | $191.00 | 11.79% | Buy |
MDGL | Madrigal Pharmaceuticals | $331.32 | $315.75 | -4.70% | Buy |
ALNY | Alnylam Pharmaceuticals | $269.95 | $254.21 | -5.83% | Buy |
RXDX | Prometheus Biosciences | $199.92 | $138.57 | -30.69% | Buy |
ZLAB Forecast FAQ
Is Zai Lab a good buy?
Yes, according to 3 Wall Street analysts, Zai Lab (ZLAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of ZLAB's total ratings.
What is ZLAB's price target?
Zai Lab (ZLAB) average price target is $75.5 with a range of $50 to $101, implying a 144.42% from its last price of $30.89. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Zai Lab stock go up soon?
According to Wall Street analysts' prediction for ZLAB stock, the company can go up by 144.42% (from the last price of $30.89 to the average price target of $75.5), up by 226.97% based on the highest stock price target, and up by 61.86% based on the lowest stock price target.
Can Zai Lab stock reach $50?
ZLAB's average twelve months analyst stock price target of $75.5 supports the claim that Zai Lab can reach $50 in the near future.
What are Zai Lab's analysts' financial forecasts?
Zai Lab's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $377.85M (high $382.28M, low $375.12M), average EBITDA is $-378M (high $-375M, low $-382M), average net income is $-315M (high $-308M, low $-324M), average SG&A $701.82M (high $713.67M, low $693.9M), and average EPS is $-3.229 (high $-3.156, low $-3.323). ZLAB's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $508.1M (high $508.1M, low $508.1M), average EBITDA is $-508M (high $-508M, low $-508M), average net income is $-188M (high $-188M, low $-188M), average SG&A $1.16B (high $1.16B, low $1.16B), and average EPS is $-1.93 (high $-1.93, low $-1.93).
Did the ZLAB's actual financial results beat the analysts' financial forecasts?
Based on Zai Lab's last annual report (Dec 2023), the company's revenue was $266.72M, which missed the average analysts forecast of $274.15M by -2.71%. Apple's EBITDA was $-367M, beating the average prediction of $-274M by 33.71%. The company's net income was $-335M, missing the average estimation of $-355M by -5.76%. Apple's SG&A was $281.61M, missing the average forecast of $487.99M by -42.29%. Lastly, the company's EPS was $-34.63, beating the average prediction of $-3.638 by 851.80%. In terms of the last quarterly report (Sep 2023), Zai Lab's revenue was $69.23M, beating the average analysts' forecast of $66.41M by 4.24%. The company's EBITDA was $-83.57M, beating the average prediction of $-66.41M by 25.84%. Zai Lab's net income was $-69.152M, missing the average estimation of $-102M by -32.14%. The company's SG&A was $68.55M, missing the average forecast of $152.17M by -54.95%. Lastly, the company's EPS was $-0.71, missing the average prediction of $-1.044 by -32.00%